Leo Pharma has announced in a press release that its emission reduction targets have been validated by the Science Based Targets initiative (SBTi), which is a collaboration between the World Resources Institute, UN Global Compact and the World Wide Fund (WWF) and more.
”Emission reduction targets are considered science-based if they are in line with what the latest climate science says is necessary to meet the goals of the Paris Agreement – to limit global warming to well-below 2 degrees Celsius above pre-industrial levels and pursue efforts to limit warming to 1.5 degrees Celsius,” the statement reads.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
(Senior) Drug Substance Specialist 
Client Talent Acquisition Specialist 
Nordic Medical Affairs Manager 
Senior Manager, Clinical Trial Budget 
Senior Chemical Safety Advisor 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Senior QA Specialist 
Biomarker Operations Lead 
Director Global Engineering 
Scientific Writer 
Project Manager & Scrum Master 
Director for innovative pre-clinical testing unit 
Clinical Project Manager 
Chemist for Incoming Materials in QC Department 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Key Account Manager, Europe and Asia 
Account Manager 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Clinical Trial Manager for development of in vitro diagnostics